Cargando…
Distinguishable Prognostic Signatures and Tumor Immunogenicity Between Pancreatic Head Cancer and Pancreatic Body/Tail Cancer
BACKGROUND: Pancreatic head cancer and pancreatic body/tail cancer are considered to have different clinical presentations and to have altered outcomes. METHODS: Ninety cases of pancreatic adenocarcinoma (PDAC) from our institution were used as a discovery set and 166 cases of PDAC from the TCGA coh...
Autores principales: | Ge, Weiyu, Ma, Jingyu, Mao, Tiebo, Xu, Haiyan, Zhang, Xiaofei, Li, Shumin, Wang, Yongchao, Yao, Jiayu, Yue, Ming, Jiao, Feng, Wang, Yu, Zhuo, Meng, Han, Ting, Hu, Jiong, Zhang, Xiao, Cui, Jiujie, Wang, Liwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213676/ https://www.ncbi.nlm.nih.gov/pubmed/35756644 http://dx.doi.org/10.3389/fonc.2022.890715 |
Ejemplares similares
-
A novel angiogenesis-based molecular signature related to prognosis and tumor immune interactions of pancreatic cancer
por: Ge, Weiyu, et al.
Publicado: (2022) -
A Novel Molecular Signature of Cancer-Associated Fibroblasts Predicts Prognosis and Immunotherapy Response in Pancreatic Cancer
por: Ge, Weiyu, et al.
Publicado: (2022) -
Prediction of Survival and Tumor Microenvironment Infiltration Based on Pyroptosis-Related lncRNAs in Pancreatic Cancer
por: Xue, Shengbai, et al.
Publicado: (2022) -
Association of aging-related genes with prognosis and immune infiltration in pancreatic adenocarcinoma
por: Xue, Shengbai, et al.
Publicado: (2022) -
HDACs/mTOR inhibitor synergizes with pyrotinib in HER2-positive pancreatic cancer through degradation of mutant P53
por: Mao, Tiebo, et al.
Publicado: (2022)